Nova Patents
CA2395593C

Azaindoles

Abstract

The invention is directed to compositions containing physiologically active compounds of general formula (I) wherein R1 is aryl or heteroaryl; R2 represents hydrogen, acyl, cyano, halo, lower alkenyl or lower alkyl optionally substituted by a substituent selected from cyano, heteroaryl, heterocycloalkyl, -Z1R8,-C(=O)-NY3Y4,-CO2R8,-NY3Y4,-N(R6)-C(=O)-R7, -N(R6)-C(=O)-NY3Y4,-N(R6)-C(=O)-OR7, -N(R6)-SO2-R7,-N(R6)-SO2-NY3Y4 and one or more halogen atoms; R3 represents hydrogen, aryl, cyano, halo, heteroaryl, lower alkyl, -C(=O)-OR5 or -C(=O)-NY3Y; and X1 represents N, CH, C-halo, C-CN, C-R7, C-NY3Y4, C-OH, C-Z2R7, C-C(=O)-OR5, C-C(=O)-NY3Y4, C-N(R8)-C(=O)-R7, C-SO2-NY3Y4, C-N(R8)-SO2-R7, C-alkenyl, C-alkynyl or C-NO2; and their produgs, and pharmaceutically acceptable salts and solvates of such compounds and their produgs, as well as to novel compounds within the scope of fomula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit protein kinases.

CA2395593C, drawing sheet 1
Sheet 1 of 50

Term

Term ended

Expired 27 December 2020, 5.7 years ago.

  1. Priority
  2. Filed
  3. Granted
  4. Expired
  5. Today

53 claims: 19 independent, 34 dependent

  1. 1
    -260 THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:1. A pharmaceutical composition comprising an effective selective kinase inhibitory amount of a compound of general formula (I): wherein:R1 represents aryl or heteroaryl each optionally substituted by one or more groups selected from acyl, alkylenedioxy, alkenyl, alkenyloxy, alkynyl, aryl, cyano, halo, hydroxy, heteroaryl, heterocycloalkyl, nitro, R4, -C(=O)-NY1Y2, -C(=O)-OR5, NY1Y2, -N(R6)-C(=O)-R7, -N(R6)-C(=O)-NY3Y4, -N(R6)-C(=O)-OR7, -N(R6)-SO2-R7, -N(R6)-SO2-NY3Y4, -SO2-NY1Y2 and -Z2R4;R2 represents hydrogen, acyl, cyano, halo, C2-4 alkenyl or C1-4 alkyl optionally substituted by a substituent selected from hydroxy, cyano, heteroaryl, heterocycloalkyl, -Z1R8, -C(=O)-NY3Y4, -CO2R8, -NY3Y4, -N(R6)-C(=O)-R7, -N(R6)-C(=O)-NY3Y4, -N(R6)-C(=O)-OR7, -N(R6)-SO2-R7, -N(R6)-SO2-NY3Y4 and one or more halogen atoms;R3 represents hydrogen, aryl, cyano, halo, heteroaryl, C1-4 alkyl, -C(=O)-OR5 or -C(=O)-NY3Y4;R4 represents alkyl, cycloalkyl or cycloalkylalkyl each optionally substituted by a substituent selected from aryl, cycloalkyl, cyano, halo, heteroaryl, heterocycloalkyl, -CHO(or a 5-, 6- or 7-membered cyclic acetal derivative thereof), -C(=O)NY1Y2, -C(=O)-OR5, -NY1Y2, -N(R6)-C(=O)-R7, -N(R6)-C(=O)-NY3Y4, -N(R6)-SO2-R7, -261 -N(R6)-SO2-NY3Y4, -OR7 and one or more groups selected from hydroxy and carboxy;R5 represents hydrogen, alkyl, alkenyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl;R6 represents hydrogen or C1-4 alkyl;R7 represents alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl;R8 represents hydrogen or C1-4 alkyl;Y1 and Y2 are independently hydrogen, alkenyl, aryl, cycloalkyl, heteroaryl or alkyl optionally substituted by one or more groups selected from aryl, halo, heteroaryl, hydroxy, -C(=O)-NY3Y4, -C(=O)-OR5, -NY3Y4, -N(R6)-C(=O)-R7, -N(R6)-C(=O)-NY3Y4, -N(R6)-SO2-R7, -N(R6)-SO2-NY3Y4 and -OR7;or the group -NY1Y2 may form a cyclic amine;Y3 and Y4 are independently hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl;or the group -NY3Y4 may form a cyclic amine;Z1 represents O or S;Z2 represents O or S(O)n;n is zero or an integer 1 or 2;and wherein (a) "acid bioisostere" means a compound in which a -COOH group is replaced by a group selected from the group consisting of -C(=O)-NHOH, -C(=O)-CH2OH, -C(=O)-CH2SH, -C(=O)-NH-CN, sulfo, phosphono, alkylsulfonylcarbamoyl, tetrazolyl, arylsulfonylcarbamoyl, heteroaryisulfonylcarbamoyl, N-methoxycarbamoyl, 3hydroxy3-cyclobutene-1,2-dione, 3,5-dioxo-1,2,4-oxadiazolidinyl, 3-hydroxyisoxazolyl and 3-hydoxy-1-methylpyrazolyl;(b) "alkyl" means, unless otherwise specified, an aliphatic hydrocarbon group which may be straight or branched chain having 1 to 15 carbon atoms in the chain, optionally substituted by one or more halogen atoms;-262 (c) "alkylene" means an aliphatic bivalent radical derived from a straight or branched alkyl group;(d) "alkenyl" means an aliphatic hydrocarbon group containing a carbon-carbon double bond and which may be straight or branched having 2 to 15 carbon atoms in the chain;(e) "alkynyl" means an aliphatic hydrocarbon group containing a carbon-carbon triple bond and which group may be a straight or branched chain having 2 to 15 carbon atoms in the chain;(f) "aryl" as a group or part of a group denotes: (i) a monocyclic or multicyclic aromatic carbocyclic moiety of 6 to 14 carbon atoms;or (ii) a partially saturated multicyclic aromatic carbocyclic moiety in which an aryl and a cycloalkyl or cycloalkenyl group are fused together to form a cyclic structure, except where otherwise defined aryl groups being optionally substituted with one or more aryl group substituents, which may be the same or different and which are selected from the group consisting of acyl, acylamino, alkoxy, alkoxycarbonyl, alkylenedioxy, alkylsulfinyl, alkylsulfonyl, alkylthio, aroyl, aroylamino, aryl, arylalkyloxy, arylalkyloxycarbonyl, arylalkylthio, aryloxy, aryloxycarbonyl, arylsulfinyl, arylsulfonyl, arylthio, carboxy or an acid bioisostere, cyano, halo, heteroaroyl, heteroaryl, heteroarylalkyloxy, heteroaroylamino, heteroaryloxy, hydroxy, nitro, trifluoromethyl, -NY3Y4, -CONY3Y4, -SO2 -NY3-C(=O)alkyl, -NY3SO2alkyl or alkyl optionally substituted with aryl, heteroaryl, hydroxy, and -NY3Y4;(g) "heteroaryl" as a group or part of a group denotes: (i) an aromatic monocyclic or multicyclic organic moiety of 5 to 10 ring members in which one or more of the ring members is/are element(s) other than carbon, optionally substituted by one or more aryl group substituents as defined in (d) except where otherwise defined;(ii) a partially saturated multicyclic heterocarbocyclic moiety in which a heteroaryl and a cycloalkyl or cycloalkenyl group are fused together to form a cyclic structure, optionally substituted by one or more aryl group substituents as defined above, except where otherwise defined;(h) "cycloalkyl" means a saturated monocyclic or bicyclic ring system of 3 to 10 carbon atoms, optionally substituted by oxo;(i) "cycloalkenyl" means a non-aromatic monocyclic or multicyclic ring system containing at least one carbon-carbon double bond and having 3 to 10 carbon atoms;-263 (j) "heterocycloalkyl" means: (i) a cycloalkyl group of 3 to 7 ring members which contains one or more heteroatoms or heteroatom-containing groups selected from O, S and NY7 and may be optionally substituted by oxo, where Y7 is hydrogen, alkyl, aryl, arylalkyl, -C(=O)-R7, -C(=O)-OR7 or -SO2R7;(ii) a partially saturated multicyclic heterocarbocyclic moiety in which an aryl or heteroaryl ring, each optionally substituted by one or more aryl group substituents, and a heterocycloalkyl group are fused together to form a cyclic structure;and (k) "cyclic amine" means a 3 to 8 membered monocyclic cycloalkyl ring system wherein one of the ring carbon atoms is replaced by nitrogen and which (i) may also contain a further heteroatom-containing group selected from O, S, SO2, or NY7, where Y7 is hydrogen, alkyl, aryl, arylalkyl, -C(=O)-R7, -C(=O)-OR7 or -SO2R7;and (ii) may be fused to additional aryl, heteroaryl, heterocycloalkyl or cycloalkyl rings to form a bicyclic or tricyclic ring system;and their corresponding N-oxides, and their ester prodrugs, and their acid bioisosteres;and pharmaceutically acceptable salts and solvates of such compounds and their N-oxides and their ester prodrugs, and their acid bioisosteres;together with one or more pharmaceutically acceptable carriers or excipients.
  2. 2
    A compound of formula (I) wherein R1, R2 and R
  3. 3
    3 are as defined in claim 1, but excluding the compounds 6-phenyl-5H-pyrrolo[2,3-b]pyrazine, 6-(4-methoxyphenyl)-5H-pyrrolo[2,3-b]pyrazine, 6-(4-chloro-phenyl)-5H-pyrrolo[2,3b]pyrazine, 6-(2chloro-phenyl)-5H-pyrrolo[2,3-b]pyrazine, 3-methyl-6-phenyl-5H-pyrrolo[2,3b]pyrazine, 2-methyl-6-phenyl-5H-pyrrolo[2,3-b]pyrazine and 7-methyl-6-phenyl5Hpyrrolo[2,3-b]pyrazine. -264 3. A compound according to claim 2 in which R1 is optionally substituted heteroaryl.
  4. 6
    A compound according to any one of claims 3-5 in which the optionally substituents within R1 are one or more groups selected from alkylenedioxy, alkenyl, alkenyloxy, aryl, cyano, halo, hydroxy, heteroaryl, heterocycloalkyl, R4, -C(=O)-NY1 Y2, -C(=O)-OR5, -NY1Y2 and -OR4.
  5. 9
    A compound according to any one of claims 2-8 in which R2 is hydrogen.
  6. 10
    A compound according to any one of claims 2-8 in which R2 is halo.
  7. 11
    A compound according to any one of claims 2-8 in which R2 is C1-4 alkyl optionally substituted by carboxy, cyano, halo, hydroxy, tetrazolyl, or CONY3Y4.
  8. 12
    A compound according to any one of claims 2-8 in which R2 is C2-4 alkenyl. -265
  9. 13
    A compound according to any one of claims 2-12 in which R3 is hydrogen.
  10. 14
    A compound according to any one of claims 2-12 in which R3 is optionally substituted aryl.
  11. 15
    A compound according to any one of claims 2-12 in which R3 is optionally substituted phenyl.
  12. 16
    A compound according to any one of claims 2-12 in which R3 is C1-4 alkyl.
  13. 37
    A compound according to claims 35 or 36 in which R3 is hydrogen, optionally substituted aryl or C1-4 alkyl.
  14. 38
    A compound according to claims any one of claims 35 to 37 in which p is 1.
  15. 48
    Use of a compound as defined in claim 2 or a corresponding ester prodrug, or a pharmaceutically acceptable salt or solvate of such a compound or an ester prodrug thereof, in the manufacture of a medicament for the treatment of a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of the catalytic activity of Syk kinase.
  16. 49
    Use of a compound as defined in claim 2 or a corresponding ester prodrug, or a pharmaceutically acceptable salt or solvate of such a compound or an ester prodrug thereof, in the manufacture of a medicament for the treatment of asthma.
  17. 50
    Use of a compound as defined in claim 2 or a corresponding ester prodrug, or a pharmaceutically acceptable salt or solvate of such a compound or an ester prodrug thereof, in the manufacture of a medicament for the treatment of psoriasis.
  18. 51
    Use of a compound as defined in claim 2 or a corresponding ester prodrug, or a pharmaceutically acceptable salt or solvate of such a compound or an ester prodrug thereof, in the manufacture of a medicament for the treatment of joint inflammation.
  19. 52
    Use of a compound as defined in claim 2 or a corresponding ester prodrug, or a pharmaceutically acceptable salt or solvate of such a compound or an ester prodrug thereof, in the manufacture of a medicament for the treatment of inflammatory bowel disease.
  20. 53
    Use of a compound as defined in claim 2 or a corresponding ester prodrug, or a pharmaceutically acceptable salt or solvate of such a compound or an ester prodrug thereof, in the manufacture of a medicament for the treatment of cancer.
Independent claims20